Feline primary pulmonary carcinomas (PPCs) occasionally exhibit a distinctive metastatic tropism for the distal digits, clinically recognized as feline lung-digit syndrome or MODAL syndrome. The molecular mechanisms driving this unique behavior remain poorly understood. This retrospective study evaluated 18 feline PPCs to investigate the expression of bone-related markers (RUNX2, osteocalcin), vimentin, Ki-67, MCK, and TTF-1. Cases were classified into PPCs with (n = 5) and without (n = 13) documented digital metastases. Adenosquamous carcinoma was the predominant histological subtype (61.1%); all tumors expressed MCK and TTF-1. While osteocalcin and aberrant vimentin expression were detected across both groups, they did not differ significantly between groups. Conversely, RUNX2 nuclear immunoreactivity was significantly elevated in cases with digital metastasis (p = 0.006). Furthermore, the evaluation of matched primary and metastatic lesions demonstrated that digital metastases retained the histological and immunophenotypic profiles of their primary tumors. Overall, this first characterization demonstrates that higher RUNX2 immunoreactivity was observed in primary pulmonary carcinomas from cats with documented digital metastasis. However, without the evaluation of extra-digital metastases, it remains undetermined whether this reflects a specific tropism for the digits or a general metastatic competence.
DNA mismatch repair (MMR) proteins have been investigated as biomarkers in human oncology, but their role in canine PPCs has not been characterized. Immunohistochemistry for MCK, TTF-1, MSH2, and MSH6 was performed and evaluated in relation to clinicopathological parameters. Affected dogs had a median age of 10.6 years. Histologically, 16 tumors were classified as adenocarcinoma and one as adenosquamous carcinoma, with papillary architecture predominating. MCK and TTF-1 immunoreactivity was detected in all cases, supporting epithelial and pulmonary differentiation when considered with histopathological and available clinical findings. Absent MSH2 immunoreactivity was observed in 17.6% of cases, whereas absent MSH6 immunoreactivity was observed in 11.8%. MSH2 expression showed a significant inverse association with tumor volume (p = 0.006), whereas no significant associations were identified between MSH6 expression and the evaluated clinicopathological parameters. As only MSH2 and MSH6 were assessed and no microsatellite instability or molecular analyses were performed, the observed abnormalities cannot be interpreted as definitive evidence of functional MMR deficiency. These findings provide preliminary data on MSH2 and MSH6 expression in canine PPCs and support further investigation using comprehensive MMR assessment and molecular approaches.
14-3-3σ is a cell-cycle regulatory protein implicated in tumor development and progression, but its expression in canine primary pulmonary carcinomas (CPPC) has not been characterized. This study investigated 14-3-3σ immunohistochemical expression in primary pulmonary carcinomas and its relationship with histological grade, proliferative activity, mitotic count, and tumor volume. Ten CPPCs were examined and graded according to established criteria. Immunohistochemical expression of 14-3-3σ was evaluated using a semiquantitative scoring system, while Ki-67 labeling was assessed by calculating the labeling index. Nine of 10 tumors (90%) showed 14-3-3σ immunoreactivity, which was predominantly multifocal, heterogeneous, and cytoplasmic; nuclear immunoreactivity was observed, particularly in areas showing strong cytoplasmic staining. Exploratory correlation analyses did not identify statistically significant associations between the 14-3-3σ immunohistochemical score and histological grade, Ki-67 labeling index, mitotic count, or estimated tumor volume. The Ki-67 labeling index ranged from 20.4% to 89.5% (median, 35.6%). These findings provide preliminary descriptive data on 14-3-3σ immunoreactivity in CPPCs. Larger studies incorporating quantitative assessment and clinical follow-up are warranted to determine its clinicopathological and prognostic significance.